



Quality For All

Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) S.A.E.'s Chief Executive Officer, Dr. Amr Morsy, recognized among the top 100 Arabian CEOs of 2020

27 January 2021 | Cairo, Egypt

Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) S.A.E., (together with its consolidated subsidiaries, "Rameda") with ticker name RMDA.CA on EGX, a leading Egyptian pharmaceutical company, announces today that its Chief Executive Officer (CEO), Dr. Amr Morsy, has been named as one of the region's leading 100 Arabian CEOs at the 2020 G2T Global Awards ceremony, which took place virtually this year.

The G2T Global Awards was established in 2016 to recognize and celebrate excellence in the Arab corporate world. The award winners are selected through a specialized merit system based on 17 specific criteria across through three primary categories: leadership, business, and community service. Dr. Amr Morsy was presented with the award in recognition of his exceptional leadership, sound management, and consistent commitment to Rameda's stakeholders that transcend beyond the company's day-to-day operations.

Dr. Amr Morsy, CEO of Rameda, commented, "It is an honour to be recognized for such a prestigious award alongside other esteemed business leaders in Egypt, such as Banque Misr CEO, Mr. Mohamed Eletreby. This year will mark a decade of my tenure with Rameda and together with my colleagues, I look forward to ensuring the company's continued success while remaining steadfast in our mission to serving our community in the best way that we can".

-Ends-

Investor Relations Contact:

Yasmine Negm
Rameda's Head of Investor Relations &
Strategic Communications
Email: yasmine.negm@rameda.com
Mobile: +20(0) 1228505050

About Rameda

Established in 1986, Rameda (RMDA.CA on EGX) is a leading Egyptian pharmaceutical company led by a team of professionals with extensive multinational experience. The company develops and produces a wide range of branded generic pharmaceuticals, nutraceuticals, food supplements and veterinary products. Rameda combines global standards with local insights and a customer-centric approach. It has developed a broad portfolio of products across multiple therapeutic areas, by successfully leveraging its strong product portfolio with its accretive product acquisitions to become one of the fastest-growing pharmaceutical players in Egypt. The company produces its wide range of dosage forms at its three manufacturing facilities located at the industrial complex in Cairo's Sixth of October Industrial Zone.



Quality For All

Forward-Looking Statements

This communication contains certain forward-looking statements. A forward-looking statement is any statement that does not relate to historical facts and events, and can be identified by the use of such words and phrases as “according to estimates”, “anticipates”, “assumes”, “believes”, “could”, “estimates”, “expects”, “intends”, “is of the opinion”, “may”, “plans”, “potential”, “predicts”, “projects”, “should”, “to the knowledge of”, “will”, “would”, or, in each case, their negatives, or other similar expressions that are intended to identify a statement as forward-looking. This applies, in particular, to statements containing information on future financial results, plans, or expectations regarding our business and management, our future growth or profitability and general economic and regulatory conditions and other matters affecting us.

Forward-looking statements reflect our management’s (“Management”) current views of future events, are based on Management’s assumptions, and involve known and unknown risks, uncertainties, and other factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by these forward-looking statements. The occurrence or non-occurrence of an assumption could cause our actual financial condition and results of operations to differ materially from, or fail to meet expectations expressed or implied by, such forward-looking statements. Our business is subject to a number of risks and uncertainties that could also cause a forward-looking statement, estimate, or prediction to become inaccurate. These risks include fluctuations in the prices of raw materials or employee costs required by our operations, its ability to retain the services of certain key employees, its ability to compete successfully, changes in political, social, legal, or economic conditions in Egypt, worldwide economic trends, the impact of war and terrorist activity, inflation, interest rate and exchange rate fluctuations, and Management’s ability to timely and accurately identify future risks to our business and manage the risks mentioned above.

Certain figures contained in this document, including financial information, have been subject to rounding adjustments. Accordingly, in certain instances, the sum or percentage change of the numbers contained in this document may not conform exactly to the total figure given.